252 related articles for article (PubMed ID: 18820805)
1. [The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications].
Barbosa JH; Oliveira SL; Seara LT
Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):940-50. PubMed ID: 18820805
[TBL] [Abstract][Full Text] [Related]
2. Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
Goh SY; Cooper ME
J Clin Endocrinol Metab; 2008 Apr; 93(4):1143-52. PubMed ID: 18182449
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products (AGEs) and diabetic vascular complications.
Yamagishi S; Nakamura K; Imaizumi T
Curr Diabetes Rev; 2005 Feb; 1(1):93-106. PubMed ID: 18220586
[TBL] [Abstract][Full Text] [Related]
4. Regulation of RAGE for attenuating progression of diabetic vascular complications.
Win MT; Yamamoto Y; Munesue S; Saito H; Han D; Motoyoshi S; Kamal T; Ohara T; Watanabe T; Yamamoto H
Exp Diabetes Res; 2012; 2012():894605. PubMed ID: 22110482
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products and diabetic complications.
Stitt AW; Jenkins AJ; Cooper ME
Expert Opin Investig Drugs; 2002 Sep; 11(9):1205-23. PubMed ID: 12225243
[TBL] [Abstract][Full Text] [Related]
6. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
7. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation endproducts and diabetes. Beyond vascular complications.
Puddu A; Viviani GL
Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):132-40. PubMed ID: 21476962
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycosylation end products in diabetic renal and vascular disease.
Bucala R; Vlassara H
Am J Kidney Dis; 1995 Dec; 26(6):875-88. PubMed ID: 7503061
[TBL] [Abstract][Full Text] [Related]
10. Serum Levels of Antibodies to Advanced Glycation End Products in Patients with Type 2 Diabetes Mellitus and Hypertension.
Nikolov A; Blazhev A; Tzekova M; Kostov K; Popovski N
Folia Med (Plovdiv); 2020 Jun; 62(2):295-301. PubMed ID: 32666760
[TBL] [Abstract][Full Text] [Related]
11. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
12. The role of advanced glycation in the pathogenesis of diabetic retinopathy.
Stitt AW
Exp Mol Pathol; 2003 Aug; 75(1):95-108. PubMed ID: 12834631
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of diabetic angiopathy--clues for innovative therapeutic interventions.
Bierhaus A; Ziegler R; Nawroth PP
Horm Res; 1998; 50 Suppl 1():1-5. PubMed ID: 9676989
[TBL] [Abstract][Full Text] [Related]
15. Skin AGEs and diabetic neuropathy.
Papachristou S; Pafili K; Papanas N
BMC Endocr Disord; 2021 Feb; 21(1):28. PubMed ID: 33622304
[TBL] [Abstract][Full Text] [Related]
16. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
Thomas MC; Baynes JW; Thorpe SR; Cooper ME
Curr Drug Targets; 2005 Jun; 6(4):453-74. PubMed ID: 16026265
[TBL] [Abstract][Full Text] [Related]
17. Blockade of diabetic vascular injury by controlling of AGE-RAGE system.
Myint KM; Yamamoto Y; Sakurai S; Harashima A; Watanabe T; Li H; Takeuchi A; Yoshimura K; Yonekura H; Yamamoto H
Curr Drug Targets; 2005 Jun; 6(4):447-52. PubMed ID: 16026264
[TBL] [Abstract][Full Text] [Related]
18. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end-products: a review.
Singh R; Barden A; Mori T; Beilin L
Diabetologia; 2001 Feb; 44(2):129-46. PubMed ID: 11270668
[TBL] [Abstract][Full Text] [Related]
20. Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
Sheetz MJ; King GL
JAMA; 2002 Nov; 288(20):2579-88. PubMed ID: 12444865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
